A lot has happened in the stock market since Liberation Day, keeping us on our toes. Volatility has declined significantly, stocks have bounced back...
Despite the uncertainty prevailing in the markets, the Nasdaq 100 Index ($NDX) has proven resilient, perhaps more so than its peer benchmarks. The 90-day...
In this market update, Frank breaks down recent developments across the S&P 500, crypto markets, commodities, and international ETFs. He analyzes bullish and bearish...
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS,...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets....
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...
In this edition of StockCharts TV‘s The Final Bar, Dave celebrates Nvidia’s rise to overtake Microsoft (MSFT) as the largest company by market cap, creating chaos...